Thermo Fisher Scientific Inc (TMO)
501.94
+2.33
(+0.47%)
USD |
NYSE |
Oct 04, 09:39
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 193.72B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -4.22% |
Valuation | |
PE Ratio | 34.31 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 4.506 |
Price to Book Value | 4.428 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | 0.35 |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.7773 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 27.23% |
Profile
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2023 (revenue figures include some cross-segment revenue): analytical technologies (16% of sales); specialty diagnostic products (10%); life science solutions (24%); and lab products and services, which includes CRO services (54%). |
URL | https://www.thermofisher.com |
Investor Relations URL | https://ir.thermofisher.com |
HQ State/Province | Massachusetts |
Sector | Healthcare |
Industry | Diagnostics & Research |
Equity Style | Large Cap/Blend |
Next Earnings Release | Oct. 26, 2023 (est.) |
Last Earnings Release | Jul. 26, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Sep. 14, 2023 |
Ratings
Profile
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2023 (revenue figures include some cross-segment revenue): analytical technologies (16% of sales); specialty diagnostic products (10%); life science solutions (24%); and lab products and services, which includes CRO services (54%). |
URL | https://www.thermofisher.com |
Investor Relations URL | https://ir.thermofisher.com |
HQ State/Province | Massachusetts |
Sector | Healthcare |
Industry | Diagnostics & Research |
Equity Style | Large Cap/Blend |
Next Earnings Release | Oct. 26, 2023 (est.) |
Last Earnings Release | Jul. 26, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Sep. 14, 2023 |